By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Igenica, Inc. 

849 Mitten Road
Suite 104
Burlingame  California  94010  U.S.A.
Phone: n/a Fax: n/a


Igenica, Inc. is a discovery-stage biopharmaceutical company focused on the creation of breakthrough antibody-based therapeutics to address the unmet medical needs of cancer patients. To this end, the company has developed two unique technology platforms that collectively offer a function-orientated screening strategy to systematically discover new tumor antigens and effective antibody drug candidates. The first platform, sTAg (surface-tagged antigen profiling), is an innovative proteomics-based technology designed to identify new surface antigens that are amenable to antibody targeting in cancer settings. The second platform, iTAb (in vivo anti-tumor antibody screening), is a monoclonal antibody production platform which provides a function-based, de novo methodology for screening monoclonal antibody drug candidates against the newly discovered antigens that are effective in eliminating or controlling cancer. Collectively, the two technology platforms drive Igenica’s drug discovery efforts and promise to identify novel and more effective cancer therapeutics. Igenica was founded in 2008 and is led by an experienced management team with Dr. Mike Rothe as CEO and Dr. Guoqing Chen as Vice President, Research. The company has long-term funding from a strong syndicate of major venture capital investors, comprising The Column Group, 5AM Ventures, and OrbiMed Advisors.

Igenica is supported by world-renowned scientific experts and advisors, including Drs. Frederick Appelbaum, David Goeddel, Thomas Kipps, Richard Klausner, Jeffrey Ravetch, Robert D. Schreiber, Richard Ulevitch, and Emil Unanue. Igenica is based in Burlingame in the San Francisco Bay Area. Igenica is currently expanding its research and development team. We have several exciting openings for scientists, postdocs and research associates/assistants, which offer excellent opportunities for highly motivated candidates to contribute significantly to the continued growth of the company. We provide a unique work environment, a competitive salary, stock options, and excellent benefits.

For further information about Igenica and our current career opportunities please visit our website at

Key Statistics

Ownership: Private

Web Site: Igenica, Inc.

Start Up

Company News
Pierre Fabre Acquires Promising Assets From Igenica, Inc. In The Field Of Immuno-Oncology 5/24/2017 8:06:18 AM
Igenica, Inc. Enters Into A Strategic Oncology Research Agreement With MedImmune (AZN) 10/28/2015 6:39:22 AM
Igenica, Inc. Awarded SBIR Grant For Next Generation Antibody Drug Conjugate Technology 8/7/2014 10:30:41 AM
Bay Area's Igenica, Inc. Follows Genentech (RHHBY) Into Antibody-Linked Cancer Drugs 4/14/2014 7:10:07 AM
Igenica, Inc. To Present At The 21st Annual BioCentury Future Leaders In The Biotech Industry 3/25/2014 7:37:39 AM
Igenica, Inc. Enrolls First Patient In Phase 1 Study Of IGN523 In Acute Myeloid Leukemia 3/18/2014 9:27:50 AM
Igenica, Inc. To Present New Data At The World ADC Summit 2/13/2014 9:53:01 AM
Bay Area's Igenica, Inc. Brings In $14 Million In Additional Series C Funding 1/28/2014 7:36:29 AM
Igenica, Inc. Appoints Oncology Expert And Industry Veteran Gwen A. Fyfe, M.D. To Board Of Directors 12/17/2013 8:41:29 AM
Igenica, Inc. Appoints Thi-Sau Migone, Ph.D., as Chief Scientific Officer 4/9/2013 8:55:43 AM